Text this: Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

  _____     ______    _  __     ___     _    _   
 / ____||  /_   _//  | |/ //   / _ \\  | || | || 
/ //---`'   -| ||-   | ' //   / //\ \\ | || | || 
\ \\___     _| ||_   | . \\  |  ___  ||| \\_/ || 
 \_____||  /_____//  |_|\_\\ |_||  |_|| \____//  
  `----`   `-----`   `-` --` `-`   `-`   `---`